Patrick Duxbury

Partner and Head of Life Sciences at Gowling WLG

Trainer

Patrick Duxbury helps clients to research, develop, manufacture and sell pharmaceutical, biotech and medical device products, using his extensive experience of structuring and executing transactions in the life sciences sector.

Patrick was a microbiologist and geneticist before re-qualifying as a lawyer in 1993 with first class honours. He now specialises in all aspects of transactional work in the life sciences sector. He has helped clients including Argenx, AstraZeneca, Astellas, MedImmune, Astex Therapeutics, Crescendo Biologics, Epidarex, ERS Genomics, GlaxoSmithKline (GSK), Heptares Therapeutics, Kymab, Immunocore and SROne on significant M&A transactions, licensing and collaboration deals and fundraisings.

Thanks to his deep knowledge of the world in which he operates, Patrick delivers his clients a unique mix of regulatory, antitrust, IP, corporate and dispute resolution advice, helping many of the sector's key players.

Deal highlights include advising AstraZeneca on its landmark collaboration agreement for the development and distribution of the University of Oxford's potential COVID-19 vaccine, a $6.9 billion cancer drug collaboration agreement with Daiichi Sankyo Company Limited, an $8.5bn oncology deal with Merck, on AstraZeneca's $300 million disposal of the rights to cancer drug Caprelsa to Genzyme and its $1.275bn collaboration with Innate Pharma. He has also recently advised Heptares Therapeutics Limited and Argenx BV, and Immunocore on several strategic license and collaboration transactions.

Patrick is a well-known speaker on topics relating to transactions in the life sciences sector. He teaches on the BIO Advanced Business Development Course in both the US and Europe.